Health Utilities in Myasthenia Gravis (P2.118)

Objective: To determine Health Utilities for patients with Myasthenia Gravis and different disease states, using the EQ5D and SF6D. The secondary objective was to determine which clinical and demographic factors drive health utilities in this population. Background: Health Utilities measure health status based on patient preferences. They range between 0, representing death and 1, representing perfect health. Health utilities are used in health care research such as in economic evaluations and have not been previously published for Myasthenia Gravis. Design/Methods: 249 patients completed disease-specific and generic measures, including the EQ5D and SF-6D. Other measures were the MGII, a measure of disease severity, the PROMIS-fatigue, a measure of overall fatigue and the MG-QOL15, a disease specific quality of life tool. Mean utilities were calculated for each MGFA class. Regression models were built to determine which clinical and personal factors are correlated with health utilities. Results: Using the EQ5D, mean utilities were: Remission: 0.98± 0.06, MM: 0.94± 0.08, I: 0.88±1.0, II:0.78±0.16, III: 0.64±0.2 and IV: 0.6± 0.22. Values were lower for the SF-6D: Remission: 0.83±0.07, MM: 0.86± 0.14, I: 0.82±0.14, II:0.67±0.12, III:0.56±0.11 and IV: 0.50±0.10. Patients with MGFA class B (bulbar) reported equal or better utilities than those in class A (limbs/axial). Utilities were correlated with symptoms (MGII score, p Conclusions: This is the first health utilities valuation study in patients with Myasthenia Gravis. These values can be used in future cost-utility studies to estimate quality adjusted life years. The patients valued their overall health as worse when having more limb rather than bulbar symptoms. The main factors associated with lower health utilities were higher disease severity, higher levels of fatigue and higher dose of prednisone. Disclosure: Dr. Barnett Tapia has nothing to disclose. Dr. Bril has received personal compensation for activities with CSL, Grifols, Bionevia, and UCB for consulting and research grants. Dr. Bayoumi has nothing to disclose.